Beam Therapeutics acquires early-stage life sciences company for 403k shares plus up to $89M milestones

Beam Therapeutics Inc.

Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).
Earnout: up to $89M in development, clinical, and commercial milestones, payable in cash or stock at Beam's discretion.
If milestones paid in stock, maximum issuable shares ~5.23M based on $17.01 closing price.
Shares issued as unregistered securities under Section 4(a)(2) exemption.
Target is an early-stage life sciences company; name not disclosed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.